Core C--Viral Vector Core

核心C--病毒载体核心

• 批准号: 6956041
• 负责人: Kyson Xiaohuai Chou
• 金额: $ 15.66万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-20 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6956041
• 关键词: Baculoviridae; Lentivirus; adeno associated virus group; biomedical facility; bioreactors; biotechnology; cell line; cystic fibrosis; equine infectious anemia virus; feline immunodeficiency virus; gene therapy; genetic transduction; heparin; plasmids; respiratory epithelium; respiratory syncytial virus; tissue /cell culture; tissue /cell preparation; transfection /expression vector

The UNC Viral Vector Core Facility is essential in our effort to develop gene therapy for cystic fibrosis and other pulmonary diseases. The Vector Core has supported the UNC Gene Therapy for Cystic Fibrosis (CF) projects since 1993 and has achieved a great deal of status in the gene therapy community as a reliable and cost-effective source of recombinant virus vector reagents. The core routinely makes available vectors that are unavailable and/or prohibitively expensive if purchased commercially. Rapid growth in demand for these reagents in recent years has brought us to a mature stage of consistent operation. We are fully staffed, wellequipped, and have the benefit of a commitment for excellent working space for the foreseeable future. These achievements have been accomplished by rapid incorporation of new technological developments as they become available, and by a commitment to making the proceeds of these technologies as widely accessible to researchers as possible. The pursuit of these goals will continue within the proposed research program. In Project 1, the Vector Core will be responsible for the large-scale production and purification of genetically shuffled and phenotypically selected chimeric rAAV vectors, thus facilitating the characterization of these reagents. Additionally, the Core will broaden its production techniques for rAAV to increase our ability to produce vectors more efficiently and on a larger scale. This will entail the use of continuous cell lines induced by helper virus infection, using mammalian as well as SF-9 insect cells. In Project 2, new EIAV producer cell lines will be used in the Vector Core to generate lentivirus vectors with greater safety and predictability. For Project 3, the Vector Core will institute production of RSV vectors as they are developed over the course of the PPG cycle. Through these functions, and in conjunction with other Cores in this application, the Vector Core will support research towards the development of safe and effective gene therapy for CF.

UNC病毒载体核心设施对于我们开发用于囊性纤维化和其他肺部疾病的基因疗法至关重要。自1993年以来，向量核心支持了囊性纤维化（CF）项目的UNC基因治疗，并在基因治疗群落中获得了很大的地位，作为重组病毒载体试剂的可靠且具有成本效益的来源。核心通常会提供不可用的矢量，如果商业购买，则不可用和/或过于昂贵。近年来，对这些试剂的需求的快速增长使我们进入了一个成熟的运行阶段。我们的人员配备人员充分，受到欢迎，并在可预见的将来对出色的工作空间的承诺受益。这些 成就是通过快速纳入新技术发展来实现的，并致力于使这些技术的收益尽可能广泛地访问。对这些目标的追求将在拟议的研究计划中继续进行。在项目1中，向量核心将负责大规模的生产和纯化遗传和表型选择的嵌合raav矢量，从而促进这些试剂的表征。此外，核心将扩大其生产技术，以使Raav提高我们更有效，更大程度地生产向量的能力。这将需要使用连续的单元线诱导 使用哺乳动物以及SF-9昆虫细胞的助手病毒感染。在项目2中，新的EIAV生产细胞系将在矢量核中使用，以产生具有更大安全性和可预测性的慢病毒载体。对于项目3，矢量核心将在PPG周期的过程中开发RSV向量。通过这些功能，并在本应用中与其他核心结合使用，矢量核心将支持研究CF开发安全有效的基因疗法的研究。